[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100461347":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":19,"locations":28,"responsibleParty":49,"collaborators":7,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":7,"eligibilityCriteria":56,"healthyVolunteers":53,"sex":57,"minAge":58,"maxAge":7,"enrollmentInfo":59,"targetDuration":7,"studyType":62,"phases":7,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":31,"whyStopped":7,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Hospital of Macerata","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","pembrolizumab plus axitinib","collect global experiences with the use of immuno-combinations in patients with metastatic RCC",[14,15,16,17,18],"nivolumab plus cabozantinib","pembrolizumab plus lenvatinib","nivolumab plus ipilimumab","avelumab plus axitinib","atezolizumab plus bevacizumab",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":7,"email":24},"Matteo Santoni, MD, PhD","CONTACT","+3907332572960","mattymo@alice.it",{"name":26,"role":22,"phone":7,"phoneExt":7,"email":27},"Giulia Sorgentoni, PhD","giulia.sorgentoni@libero.it",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Ospedale di Macerata, UOC Oncologia","RECRUITING","Province of Macerata","Macerata","62100","Italy","IT",{"type":38,"coordinates":39},"Point",[40,41],13.45293,43.29789,{"lat":41,"lon":40},[44,45,47],{"name":21,"role":22,"phone":7,"phoneExt":7,"email":7},{"name":26,"role":22,"phone":46,"phoneExt":7,"email":27},"+3907332573752",{"name":21,"role":48,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"type":50,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100461347","international-multicentric-study-aron-1-100461347",false,"NCT05287464","International Multicentric Study ARON-1","Inclusion Criteria:\n\n* Patients aged \\>18y\n* Cytological or Histologically confirmed diagnosis of clear cell or non-clear cell RCC\n* Histologically or radiologically confirmed diagnosis of metastatic disease\n* First-line treatment with nivolumab plus ipilimumab or nivolumab plus cabozantinib or pembrolizumab plus axitinib or pembrolizumab plus lenvatinib or avelumab plus axitinib or atezolizumab plus bevacizumab\n\nExclusion Criteria:\n\n* Patients without histologically confirmed diagnosis of RCC\n* Patients without histologically or radiologically confirmed metastatic disease\n* Patients treated with immuno-combinations not included in the list reported in the Inclusion Criteria Section","ALL","18 Years",{"count":60,"type":61},1220,"ESTIMATED","OBSERVATIONAL","The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC.\n\nTwo Supplementary Studies (ARON-1α and ARON-1β) have been designed. The ARON-1α Supplementary Study has been designed to investigate for the presence of genomic signatures from tumor samples of patients treated with first-line immuno-combinations for advanced RCC. The ARON-1β Supplementary Study has been designed to charaterize the immune cell populations and assess their relationship with the clinical outcome of mRCC patients treated with first-line immuno-combinations",[65],"Metastatic Renal Cell Carcinoma (mRCC)",[67,68,69,70,71],"immunotherapy","mRCC","immuno-combinations","artificial intelligence technology","real-world data","2025-11-19",{"date":74,"type":75},"2025-11-26","ACTUAL",{"date":77,"type":75},"2022-03-10",{"date":79,"type":61},"2027-09-30",{"name":5,"class":6},1]